Key result
CSL112 significantly enhances cholesterol efflux capacity and HDL-C levels without increasing adverse events.
Why the study?
Does CSL112 improve HDL-related biomarkers and reverse cholesterol transport without increasing adverse events in adults at risk of atherosclerotic CVD?
Meta-Analysis
Does CSL112 improve HDL-related biomarkers and reverse cholesterol transport without increasing adverse events in adults at risk of atherosclerotic CVD?
p-value: p=< 0.00001
CSL112 enhances cholesterol efflux capacity and HDL-C levels without increasing adverse events, suggesting potential as an adjunctive therapy for immediate cardiovascular protection.
BACKGROUND: Despite statin therapy, cardiovascular disease remains a leading cause of mortality. CSL112 enhances HDL function and reverse cholesterol transport, offering a novel strategy for atherosclerotic cardiovascular disease (CVD). METHODS: Following PRISMA guidelines, databases including PubMed, the Cochrane Library, Scopus, Google Scholar and EMBASE were searched from inception to May 2025 for studies evaluating efficacy and safety of CSL112 in adults at risk of Atherosclerotic CVD. Data were analyzed using RevMan version 5.4 with a random-effects model. RESULTS: < 0.00001) without meaningful change in apolipoprotein A-I. Safety analyses showed no increased risk of serious adverse events (RR 1.05) or treatment-emergent adverse events (RR 0.88) versus placebo. CONCLUSION: CSL112 significantly enhances CEC and HDL-C levels with favorable safety profile with the 6 g dose at 2 hours, supporting its use as adjunctive therapy for immediate cardiovascular protection. Large outcome-driven trials are warranted to define long-term clinical benefits.
No takes yet. Share an insight, caveat, or question.
Fatima et al. (2026) conducted a meta-analysis in Atherosclerotic cardiovascular disease. CSL112 vs. placebo was evaluated on CEC and HDL-C levels (p=< 0.00001). CSL112 significantly enhanced CEC and HDL-C levels (P<0.00001) without increasing serious adverse events (RR 1.05) or treatment-emergent adverse events (RR 0.88) compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: